- Low
- 51,000
- Average
- 51,000
- Median
- 51,000
- High
- 51,000
Igenica Salary
13
58
75
Igenica average salary is $51,000, median salary is $51,000 with a salary range from $51,000 to $51,000.
Igenica salaries are collected from government agencies and companies. Each salary is associated with a real job position. Igenica salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Igenica salaries are collected from government agencies and companies. Each salary is associated with a real job position. Igenica salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
| Job Title | Salaries | City | Year | More info |
| Regional Manager | 51,000-51,000 | Itasca, IL, 60143 | 2012 | Igenica Regional Manager Salaries (1) Igenica Itasca, IL Salaries |
Related Igenica Salary
Calculate how much you could earn
It's FREE. Based on your input and our analysis. How we do it?
All fields are required for calculation accuracy.
- We will send you an email to access your personalized report.
- We won’t share your email address
Igenica salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.
Real Jobs Salary - Salary List- 8.5 million company & government reported salaries with date & location
- Salary calculator rank & calculate your salary
- 151 million W-2s pay scale statistics in U.S.
- Salary Map helps you navigate location based salary information
- State & City Salary provides wage data by metropolitan areas
- Company Salaries has salaries data from over 200,000 companies
Guyp Salary Igenica Jobs
| See more Igenica Jobs» | |
| Search All Jobs | |
Patents information
71
All Patents
4
Grant Patents
64
Patents Pending
12
Patents Families
More Recent
Igenica... Information
- Igenica
- Industry: BioTech/Drugs
- City: Burlingame, CA
- Igenica is a biopharmaceutical company dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer. Although recombinant monoclonal antibodies (mAbs) are considered to be one of the most promising immunologic approaches to therapy, relatively few products have been approved for use in humans. In fact, there appears to be an increasing reliance on an ageing and overlapping portfolio of mAb drugs and drug targets, discovered by a process that has evolved very little over the past two decades. Igenica contends that the key to next generation mAb-based medicines lies in both the
